Catalyst Event
Eli Lilly and Co (LLY) · Other
From KEDI Global Longevity Bio Index (KGLB)
5/28/2026, 12:00:00 AM
CVS Caremark announced it will add Lilly's obesity drugs Foundayo and Zepbound to its preferred formularies, significantly expanding patient access; high impact due to increased market share expected
Korean Translation
주요 의약품 관리 업체(PBM)인 CVS 케어마크가 릴리의 비만 치료제 파운다요(Foundayo)와 젭바운드(Zepbound)를 선호 의약품 목록에 추가하여 접근성을 확대함. 시장 점유율 확대에 따른 높은 시장 영향이 예상됨
Related Recent Events
Exelixis Inc (EXEL) · Other
U.S. FDA PDUFA target action date for zanzalintinib (December 3, 2026) is a potential first approval for a major new franchise; >10% price impact is estimated, scheduled.
12/3/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Other
The U.S. FDA set a PDUFA target action date for iberdomide on 2026-08-17; importance is Low as the setting of a PDUFA date is a procedural event with minor price impact.
8/17/2026, 12:00:00 AM
Moderna Inc (MRNA) · Other
FDA Prescription Drug User Fee Act (PDUFA) target action date for its seasonal flu vaccine (mRNA-1010) on August 5, 2026; Medium importance as PDUFA dates are major catalysts for biotech stocks, scheduled.
8/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Next quarterly earnings for Q2 2026 are expected to be announced on August 4, 2026; medium impact estimated based on historical volatility during earnings releases, expected.
8/4/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
Sanofi's Q2 2026 earnings results release on July 30, 2026, is expected to have a Medium impact as earnings typically drive 5-10% price volatility scheduled.
7/30/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Earnings Release
Q2 2026 earnings release for 2026-07-30. Low importance as it is a routine announcement scheduled.
7/30/2026, 12:00:00 AM